NCT04892277 - CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

March 27, 2028

Study Completion Date

March 27, 2040

Conditions

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRefractory B-Cell Non-Hodgkin LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic LymphomaRefractory Transformed Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563

Given IV

DRUG

Bendamustine

Given IV

PROCEDURE

Biospecimen Collection

Undergo collection of blood and tissue samples

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo CT/PET

Trial Locations (1)

55905

RECRUITING

Mayo Clinic in Rochester, Rochester